Inve India ▾

Orchid Pharma share price & results

Orchid Pharma Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vertically integrated cephalosporin antibiotics maker - from fermentation intermediates to APIs to finished dosage formulations.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue304 ₹ crore+15.6% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin4.6 %+6.8 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit3.2 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity1.17 %−9.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-20.68 %−13.3 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.09 %−82.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

0 of 11 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Orchid Pharma Limited management guidance track record on Inve: 25 targets tracked across analysed earnings calls (0 achieved, 11 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
Enmetazobactam Lifetime Sales$2 billion to $3 billion
Call transcript, Q2 FY25 · 11 Nov 2024		Q2 FY25Q1 FY27:The overall lifetime sales target of $1-2 billion was not mentioned. Management provided a 10-year value of ~$178 million for a specific licensing arrangement in Russia.
Call transcript, Q1 FY27 · 24 Aug 2026		Ghosted
Teflaro & Avycaz US FilingThis year or early next year
Call transcript, Q3 FY26 · 12 Feb 2026		Q3 FY26Q1 FY27:Regarding Zavicefta (Avycaz), management now expects 'validation batches maybe this year or early next year, and then six months for filing.' This pushes the filing timeline to mid-to-late 2027, beyond the original target.
Call transcript, Q1 FY27 · 24 Aug 2026		Delayed
7ACA Plant CommissioningApril '26
Call transcript, Q2 FY25 · 11 Nov 2024		Q2 FY25Q1 FY27:We target commissioning by December of '26, followed by validation and initial batches during January to March '27 period. Our objective remains unchanged, commissioning and the first commercial batch by March of '27.
Call transcript, Q1 FY27 · 24 Aug 2026		On Track

Source: Inve Guidance Tracker for Orchid Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

11 of Orchid Pharma Limited's 25 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 22 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹835.35 +2.08% · +₹17

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +16.0% 1Y

₹0.6k₹0.8k₹1.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 12 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 24 Aug 2026

1Y: ₹720.25 on 24 Oct 2025 → ₹835.35. High ₹1,107.2 (22 Sept 2026), low ₹482.45 (30 Mar 2026).

Previous close
₹818.35
Market cap
₹4.9k Cr
52-week range
₹482.45 – ₹1,107.2
One year
+17.02%
Price to earnings (TTM to Jun 2026)
276.42×
Return on equity (TTM to Jun 2026)
1.17%

Overview

Symbol
NSE:ORCHPHARMA
Exchange
NSE
Currency
INR

What Orchid Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Orchid Pharma manufactures and exports cephalosporin antibiotic active pharmaceutical ingredients (APIs) spanning all five generations, along with finished dosage formulations (oral and sterile injectables) and veterinary products, earning through global regulated and emerging-market sales. It also develops and licenses its own novel antibiotic molecule (Enmetazobactam, branded EXBLIFEP/Orblicef) invented in-house. The company operates a single reported business segment - cephalosporin pharmaceuticals - and is vertically integrating backward into 7-ACA (a key fermentation-derived intermediate) to reduce import dependence.

Segments

  • Cephalosporin Pharmaceuticals
One of only three USFDA-approved sterile cephalosporin manufacturing facilities in the world
1 of 3 globally
Cephalosporin product range covered
44 of 50 cephalosporins ever invented
API manufacturing complex
Alathur, near Chennai, Tamil Nadu - one of India's largest integrated antibiotic manufacturing complexes
Facility size and blocks
60-acre facility with 5 sterile and 7 oral production blocks
US Drug Master Filings (DMF)
48 cumulative (30 Cephalosporin, 18 NPNC segment)
ANDAs held (US)
6
Founded 1992Headquarters Chengalpattu district, Tamil Nadu, India Company website

How the price took the results

close before → close after

Q1 FY27
+3.6%
24 Aug
Q4 FY26
−1.9%
1 Jun
Q3 FY26
−2.6%
12 Feb
Q2 FY26
−2.7%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Orchid Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Orchid Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Orchid Pharma Limited

Guides on how to read this kind of business and the numbers that matter.